ZURICH (Reuters) – Swiss drugs industry supplier Lonza plans to cut 500 jobs, including 400 at its main plant in southern Switzerland, as it grapples with low-cost competition, a strong Swiss franc and higher raw material prices.
The cuts at the Basel-based firm, which makes pharmaceutical ingredients for drugmakers such as GlaxoSmithKline and Abbott, equate to around 5 percent of its global workforce of about 11,000.
ZURICH (Reuters) – Swiss dental implant maker Straumann (STMN.S: Quote, Profile, Research, Stock Buzz) said it would axe roughly 150 jobs to boost margins as it grapples with sluggish demand in Europe, its biggest market.
The euro zone debt crisis has battered sales of dental implants made by Straumann and its Swiss rival Nobel Biocare (NOBN.S: Quote, Profile, Research, Stock Buzz) as cash-strapped Europeans, worried about the downturn, cut back on non-essential dental treatment.
ZURICH, Oct 25 (Reuters) – Delays to restarting production
at the U.S. factory that makes Novartis AG’s popular
migraine medicine Excedrin are turning into a major headache for
the Swiss drugmaker’s boss.
Joseph Jimenez is so fed up with having to push back the
timeline to restart manufacturing at its consumer health site in
Lincoln, Nebraska that he’s given up making forecasts.
ZURICH, Oct 25 (Reuters) – Swiss drugmaker Novartis
said flu vaccines that Italy has banned from sale are
safe and it does not expect other countries to take similar
Italy banned four anti-influenza vaccines produced by
Novartis on Wednesday pending tests for possible side effects
after small particles were found in some of the injections.
ZURICH, Oct 24 (Reuters) – Swiss business is rallying to
arms to defend top managers’ pay as the government set a date on
Wednesday for a referendum that may impose the world’s first law
forcing companies to accept any limits shareholders place on
Coming after the near wreck of banking giant UBS was blamed
on a lavish bonus culture that drove its managers to take too
many risks, the initiative’s opponents say that, far from
rescuing Switzerland’s reputation for financial success, it will
drive away investment and cause an exodus of talent.
ZURICH, Oct 24 (Reuters) – A new lung and heart drug from
Actelion prolonged overall survival by more than a
third in a clinical trial, reassuring Europe’s leading biotech
company that it has a viable successor to its current top
The Swiss company is banking on macitentan to replace
Tracleer, which also treats pulmonary arterial hypertension
(PAH) and currently accounts for around 90 percent of group
sales. Tracleer goes off patent from 2015 and faces growing
competition from Gilead’s Letairis.
ZURICH, Oct 24 (Reuters) – Actelion’s experimental
lung drug macitentan prolonged overall survival by more than a
third according to detailed study data, which the company hopes
will convince investors it has a viable follow-up product to
secure its commercial future.
Europe’s largest standalone biotech company wants the drug,
which treats pulmonary arterial hypertension — a disease that
causes high blood pressure in the arteries of the lungs — to
replace blockbuster Tracleer.
ZURICH (Reuters) – A tax system that has attracted wealthy foreigners like Phil Collins and Michael Schumacher to live in Switzerland will be put to a vote to see if the people want to scrap it.
An alliance of left-wing parties and trade unions said on Friday they had collected the 100,000 signatures needed to put their proposal, “Enough with tax privileges for millionaires”, to a referendum.
ZURICH (Reuters) – Hopes for a key new heart and lung drug overshadowed nine-month results from Actelion Ltd, which showed a modest 4 percent slide in sales of the Swiss group’s current mainstay Tracleer.
Europe’s largest biotechnology company said on Thursday net income rose a higher-than-expected 16 percent, helped by cost cutting, prompting it to reiterate its 2012 outlook.
ZURICH (Reuters) – Swiss drugmaker Roche Holding AG is banking on a new generation of breast cancer medicines to drive sales growth after strong demand for its established cancer treatments helped it to top forecasts in the third quarter.
Most of Roche’s best-selling cancer drugs do not face imminent generic competition, sparing it the pain from a wave of patent expiries currently sweeping the global drugs industry.